Coordinating partner

Guillaume Canaud (MD, PhD), RHU COSY scientific coordinator, works in the Renal Division of Necker Hospital and runs the laboratory entitled “Mechanisms and therapeutic strategies in overgrowth syndromes and vascular anomalies”, located within the Institut Necker-Enfants Malades (INEM).
He performed his Residency in Nephrology in Paris. He carried out his PhD degree in molecular and cellular biology at the laboratory of Dr. Fabiola Terzi (INSERM U1151, Necker – Enfants Malades Hospital). Then, he joined Joseph Bonventre’s Laboratory (Harvard Medical School, Boston, USA) to achieve a postdoc.

He came back to Christophe Legendre’s team with a Faculty position (Associate Professor) and built his own research group dedicated to translational medicine. He obtained the prestigious European Research Council starting grant (2016) and an ERC Proof of Concept Grant (2017). He received numerous awards including the 2018 Prize Jean Lecocq of the French Academy of Sciences, the 2019 Prize Eloi Collery of the French Academy of Medicine (highest distinction of the National Academy) and the 2019 Ville de Paris Jean Hamburger Prize.

Throughout his career, Guillaume has demonstrated his leadership in coordinating patient care and fundamental research.

Guillaume Canaud leads the laboratory entitled “Precision medicine for diseases of the mTOR pathway” specialized in the understanding of rare disorders linked to the mTOR pathway as well as identification of new treatment for patients. The lab is located within the Institut Necker-Enfants Malades (INEM). INEM is an international biomedical research center located on the Necker Hospital campus and supported by the French National Institute of Health and Medical Research (INSERM-U1151), the French National Center for Scientific Research (CNRS) and the University Paris Descartes.

One of INEM’s major strengths is the close interaction between the research labs and the clinical departments, creating a highly dynamic environment and promoting translational and “bench to bedside” activities.

Guillaume Canaud, as the project coordinator (Inserm partner), will take part in the management of the project (WP1) with the support of Inserm Transfert, a private subsidiary of Inserm under a Public Service Delegation agreement, and the Délégation Régionale Inserm Paris 5 (DR5), a Coordinator that provides logistical support for research structures.

Dr Canaud (sponsored by Inserm) will lead WP3, as such he will work to develop appropriate animal models, test novel pharmacological treatments, and decipher the molecular signature and putative biomarkers of Overgrowth syndromes (OS).

At the same time, as an AP-HP partner, he will be highly involved in all the tasks that concern the delineation and natural history of OS (WP4) and the reorganization of healthcare for OS patients (WP5) but also will participate on the creation of standardized protocols of MRI (Magnetic Resonance Imaging) and elaboration of new tools to explore and follow up bone composition/deformation as well as soft tissue composition and creating a 3D personalized virtual patient (WP6).